INNATE PHARMA SA-SPONS ADR (IPHA)
US45781K2042 - ADR
We assign a fundamental rating of 2 out of 10 to IPHA. IPHA was compared to 568 industry peers in the Biotechnology industry. IPHA has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, IPHA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
IPHA had negative earnings in the past year.
In the past year IPHA has reported a negative cash flow from operations.
IPHA had negative earnings in each of the past 5 years.
IPHA had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -22.48%, IPHA is in the better half of the industry, outperforming 74.51% of the companies in the same industry.
IPHA has a Return On Equity (-118.25%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.48% | ||
| ROE | -118.25% | ||
| ROIC | N/A |
ROA(3y)-17.27%
ROA(5y)-15.56%
ROE(3y)-57.01%
ROE(5y)-44.32%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 88.00%, IPHA belongs to the top of the industry, outperforming 91.15% of the companies in the same industry.
In the last couple of years the Gross Margin of IPHA has remained more or less at the same level.
IPHA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.32%
GM growth 5Y-0.15%
2. Health
2.1 Basic Checks
IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IPHA has been increased compared to 1 year ago.
The number of shares outstanding for IPHA has been increased compared to 5 years ago.
Compared to 1 year ago, IPHA has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -2.62, we must say that IPHA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IPHA (-2.62) is comparable to the rest of the industry.
A Debt/Equity ratio of 2.73 is on the high side and indicates that IPHA has dependencies on debt financing.
With a Debt to Equity ratio value of 2.73, IPHA is not doing good in the industry: 82.83% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.73 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.62 |
ROIC/WACCN/A
WACC7.2%
2.3 Liquidity
A Current Ratio of 2.92 indicates that IPHA has no problem at all paying its short term obligations.
IPHA has a Current ratio of 2.92. This is in the lower half of the industry: IPHA underperforms 66.19% of its industry peers.
A Quick Ratio of 2.92 indicates that IPHA has no problem at all paying its short term obligations.
IPHA's Quick ratio of 2.92 is on the low side compared to the rest of the industry. IPHA is outperformed by 64.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.92 | ||
| Quick Ratio | 2.92 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 46.50% over the past year.
IPHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -43.07%.
Measured over the past years, IPHA shows a decrease in Revenue. The Revenue has been decreasing by -8.27% on average per year.
EPS 1Y (TTM)46.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1531.56%
Revenue 1Y (TTM)-43.07%
Revenue growth 3Y-2.59%
Revenue growth 5Y-8.27%
Sales Q2Q%-76.54%
3.2 Future
The Earnings Per Share is expected to grow by 36.16% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 26.37% on average over the next years. This is a very strong growth
EPS Next Y28.59%
EPS Next 2Y39.4%
EPS Next 3Y36.16%
EPS Next 5YN/A
Revenue Next Year-18.64%
Revenue Next 2Y28.48%
Revenue Next 3Y34.63%
Revenue Next 5Y26.37%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IPHA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPHA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IPHA's earnings are expected to grow with 36.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.4%
EPS Next 3Y36.16%
5. Dividend
5.1 Amount
IPHA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INNATE PHARMA SA-SPONS ADR
NASDAQ:IPHA (12/18/2024, 12:03:32 PM)
2.16
+0.01 (+0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap174.85M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.48% | ||
| ROE | -118.25% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.73 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.92 | ||
| Quick Ratio | 2.92 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)46.5%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y28.59%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-43.07%
Revenue growth 3Y-2.59%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y